Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced BRAF-mutant Cancers 1

Interventions

pembrolizumab 8Cetuximab 8Cisplatin 6Fluorouracil 5Paclitaxel 4durvalumab 3Radiotherapy 3Leucovorin 3Docetaxel 3Carboplatin 3tremelimumab 2niraparib 2avelumab 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Nivolumab 2Ipilimumab 2Bevacizumab 2zalutumumab 1yeast-CEA vaccine 1spartalizumab 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1regorafenib 1penpulimab 1paclitaxel poliglumex 1osimertinib 1necitumumab 1dostarlimab 1demplatin pegraglumer 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Squamous Cell × PX-866 × Clear all
NCT01252628 2018-05-16

Phase 1 and 2 Study of PX-866 and Cetuximab

Seagen Inc.

Phase 1/2 Completed
178 enrolled
Gastrointestinal

Carcinoma, Squamous Cell, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡